Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Feb;31(2):191–196. doi: 10.1128/aac.31.2.191

Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients.

C S Verhagen, B de Pauw, T de Witte, J Janssen, K Williams, P de Mulder, T Bothof
PMCID: PMC174690  PMID: 3551829

Abstract

In a prospective randomized study, ceftazidime monotherapy was compared with a combination of ceftazidime plus cephalothin in 102 febrile neutropenic patients. Thirty bacteriologically documented infections, of which 23 were bacteremias, in 48 clinically assessable patients were treated with ceftazidime alone. Twenty-four bacteriologically proven infections, of which 18 were bacteremias, in 42 clinically assessable patients were treated with a combination of ceftazidime and cephalothin. The clinical response rates in assessable patients were 77% for ceftazidime monotherapy and 88% for the combination. The bacteriological clearance rate was 70% for ceftazidime monotherapy and 79% for the combination. Efficacy against gram-negative pathogens appeared to be excellent, with 93% clearance for ceftazidime monotherapy and 100% clearance for the combination. The bacteriological clearance of gram-positive infections was only 60% for both regimens, with failures mainly due to Streptococcus faecalis and Streptococcus sanguis, which are primarily resistant to both ceftazidime and cephalothin. After addition of vancomycin to those infections which did not respond to empiric therapy, bacteriological clearance rates of 94% (ceftazidime plus vancomycin) and 90% (ceftazidime and cephalothin plus vancomycin) were achieved. Three superinfections were registered in the ceftazidime group and two were seen in the combination group. Other adverse effects of ceftazidime were minimal and were not enhanced by combination with cephalothin. It is concluded that ceftazidime is an effective drug for the empiric treatment of febrile neutropenic patients, especially if one is prepared to modify therapy if resistant gram-positive strains or mycotic infections are encountered. Neither the clinical nor bacteriological cure rates could be substantially improved by adding cephalothin to ceftazidime in initial empiric treatment of febrile neutropenic patients.

Full text

PDF
191

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  2. Bodey G. P., Buckley M., Sathe Y. S., Freireich E. J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966 Feb;64(2):328–340. doi: 10.7326/0003-4819-64-2-328. [DOI] [PubMed] [Google Scholar]
  3. Donnelly J. P., Marcus R. E., Goldman J. M., Cohen J., Worsley A. M., Catovsky D., Darrell J. H., Want S. V., Galton D. A. Ceftazidime as first-line therapy for fever in acute leukaemia. J Infect. 1985 Nov;11(3):205–215. doi: 10.1016/s0163-4453(85)93063-4. [DOI] [PubMed] [Google Scholar]
  4. Fainstein V., Bodey G. P., Elting L., Bolivar R., Keating M. J., McCredie K. B., Valdivieso M. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):101–110. doi: 10.1093/jac/12.suppl_a.101. [DOI] [PubMed] [Google Scholar]
  5. Fu K. P., Neu H. C. The role of inducible beta-lactamases in the antagonism seen with certain cephalosporin combinations. J Antimicrob Chemother. 1981 Jan;7(1):104–107. doi: 10.1093/jac/7.1.104. [DOI] [PubMed] [Google Scholar]
  6. Meyers B. R. Comparative toxicities of third-generation cephalosporins. Am J Med. 1985 Aug 9;79(2A):96–103. doi: 10.1016/0002-9343(85)90268-2. [DOI] [PubMed] [Google Scholar]
  7. Neu H. C. Relation of structural properties of beta-lactam antibiotics to antibacterial activity. Am J Med. 1985 Aug 9;79(2A):2–13. doi: 10.1016/0002-9343(85)90254-2. [DOI] [PubMed] [Google Scholar]
  8. Norris S. M., Guenthner S. H., Wenzel R. P. Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures. J Antimicrob Chemother. 1985 Aug;16(2):183–188. doi: 10.1093/jac/16.2.183. [DOI] [PubMed] [Google Scholar]
  9. Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. doi: 10.1056/NEJM198608283150905. [DOI] [PubMed] [Google Scholar]
  10. Pizzo P. A., Thaler M., Hathorn J., Hiemenz J., Skelton J., McKnight J., Rubin M., Browne M., Longo D., Cotton D. New beta-lactam antibiotics in granulocytopenic patients. New options and new questions. Am J Med. 1985 Aug 9;79(2A):75–82. doi: 10.1016/0002-9343(85)90265-7. [DOI] [PubMed] [Google Scholar]
  11. Rolinson G. N. Beta-lactam antibiotics. J Antimicrob Chemother. 1986 Jan;17(1):5–36. doi: 10.1093/jac/17.1.5. [DOI] [PubMed] [Google Scholar]
  12. Young L. S. Double beta-lactam therapy in the immunocompromised host. J Antimicrob Chemother. 1985 Jul;16(1):4–6. doi: 10.1093/jac/16.1.4. [DOI] [PubMed] [Google Scholar]
  13. de Pauw B. E., Kauw F., Muytjens H., Williams K. J., Bothof T. Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):93–99. doi: 10.1093/jac/12.suppl_a.93. [DOI] [PubMed] [Google Scholar]
  14. de Pauw B., Williams K., de Neeff J., Bothof T., de Witte T., Holdrinet R., Haanen C. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother. 1985 Dec;28(6):824–828. doi: 10.1128/aac.28.6.824. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES